Torthaí cuardaigh - Jae‐Cheol Jo

  • 1 - 12 toradh as 12 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Plasmacytoid dendritic cell neoplasms

    Plasmacytoid dendritic cell neoplasms de réir Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, Jae‐Cheol Jo

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death

    Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death de réir Sook‐Kyoung Heo, Eui‐Kyu Noh, Jeong Yi Kim, Yoo Kyung Jeong, Jae‐Cheol Jo, Yunsuk Choi, Su‐Jin Koh, Jin Ho Baek, Young Joo Min, Hawk Kim

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

    Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma de réir Ho‐Young Yhim, Jin Seok Kim, Yeung‐Chul Mun, Joon Ho Moon, Yee Soo Chae, Yong Park, Jae‐Cheol Jo, Seok Jin Kim, Dok Hyun Yoon, June‐Won Cheong, Jae-Yong Kwak, Je‐Jung Lee, Won Seog Kim, Cheolwon Suh, Deok‐Hwan Yang

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

    Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial) de réir Keun-Wook Lee, Ik‐Joo Chung, Min‐Hee Ryu, Young Iee Park, Byung‐Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae‐Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang‐Hee Cho, Yoon‐Koo Kang

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer

    Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer de réir Jong‐Mu Sun, Yong Chan Ahn, Eun Kyung Choi, Myung‐Ju Ahn, Jin Seok Ahn, Se‐Hoon Lee, Daniel Lee, Hongryull Pyo, Si Yeol Song, Sin‐Ho Jung, Jaemin Jo, Jae‐Cheol Jo, Hee-Jung Sohn, Cheolwon Suh, Joong Sun Lee, Seung‐Whan Kim, K. Park

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

    Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of... de réir Saad Z. Usmani, María‐Victoria Mateos, Suzanne Lentzsch, Hang Quach, Marcelo Capra, Roberto Ovilla, Jae‐Cheol Jo, Ho‐Jin Shin, Pieter Sonneveld, Ming Qi, Himal Amin, Jianping Wang, Xiang Qin, Linda Okonkwo, Jon Ukropec, Sonali Trivedi, Kenshi Suzuki, Meletios Α. Dimopoulos, Michèle Cavo, Ajay K. Nooka, Ajai Chari, Thierry Façon

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    POSTER: MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3

    POSTER: MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Pha... de réir Natalie S. Callander, Paul G. Richardson, Marek Hus, Vincent Ribrag, Joaquín Martínez‐López, Kihyun Kım, Jae Hoon Lee, M.A.C. Dimopoulos, Fredrik Schjesvold, Thierry Façon, Jae‐Cheol Jo, Chang‐Ki Min, Michał Mielnik, Shinta Cheng, L.M. Smith, Caroline J. Breitbach, Christopher D. Brawley, Harjeet Sembhi, John LaMacchia, Shawn Hakim, Brandon E. Kremer, Sebastian Grosicki

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk de réir Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet‐Loiseau, Tomer M. Mark, Ivan Špıčka, Tamás Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vânia Hungria, Michèle Cavo, Je‐Jung Lee, Ajay K. Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Asher Chanan‐Khan, Noemi Horvath, Marcelo Capra, Meral Beksaç, Roberto Ovilla, Jae‐Cheol Jo, Ho‐Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, María‐Victoria Mateos

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

    Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR de réir Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet‐Loiseau, Tomer M. Mark, Ivan Špıčka, Tamás Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vânia Hungria, Michèle Cavo, Je‐Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Emma C. Scott, Asher Chanan‐Khan, Noemi Horvath, Marcelo Capra, Meral Beksaç, Roberto Ovilla, Jae‐Cheol Jo, Ho‐Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, María‐Victoria Mateos

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

    Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia de réir Sang Eun Yoon, Yuqin Song, Seok Jin Kim, Dok Hyun Yoon, Tsai‐Yun Chen, Youngil Koh, Ka‐Won Kang, Ho Sup Lee, Kevin Tay, Soon Thye Lim, M. Poon, Cosphiadi Irawan, Weili Zhao, Young Rok, Mark Hong Lee, Soo Chin Ng, Won Sik Lee, Ye Guo, Huilai Zhang, Hye Jin Kang, Hwan‐Jung Yun, Hyo Jung Kim, Daryl Tan Chen Lung, Jae-Yong Kwak, Jae Joon Han, Yeung‐Chul Mun, Sung Yong Oh, Hyeok Shim, Jung Hye Kwon, Byeong Seok Sohn, Seong Kyu Park, Jae-Cheol Jo, Young Hyeh Ko, Zhu Jun, Won Seog Kim

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

    Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymph... de réir Yunlin Zhang, Ruchi P. Patel, Ki Hyun Kim, Hyungwoo Cho, Jae‐Cheol Jo, Seong Hyun Jeong, Sung Yong Oh, Yoon Seok Choi, Sung Hyun Kim, Ji Hyun Lee, Mathew G. Angelos, Puneeth Guruprasad, Ivan Cohen, Ositadimma Ugwuanyi, Yong Gu Lee, Raymone Pajarillo, Jong Hyun Cho, Alberto Carturan, Luca Paruzzo, Guido Ghilardi, Michael Wang, Soohwan Kim, Sung‐Min Kim, Hyun‐Jong Lee, Ji‐Ho Park, LeiGuang Cui, Taebum Lee, In-Sik Hwang, Young‐Ha Lee, Yongjun Lee, Patrizia Porazzi, Dongfang Liu, Yoon Lee, Jong‐Hoon Kim, Jong-Seo Lee, Dok Hyun Yoon, Junho Chung, Marco Ruella

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

    Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions de réir Sung‐Hoon Jung, Young‐Il Koh, Min Kyoung Kim, Jin Seok Kim, Joonho Moon, Chang‐Ki Min, Dok Hyun Yoon, Sung Soo Yoon, Je‐Jung Lee, Chae Moon Hong, Ka‐Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok, Yeung‐Chul Mun, Sung‐Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon‐Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-Won Lee, Jun Ho Yi, Ji Yun Lee, Ji‐Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho‐Young Yhim, Yoon Hwan Chang, Jae‐Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee Jeong Cho, Andrew C. Ahn, Jong Han Choi, Byoung Kwon Kim, Kihyun Kım

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: